Citations

Showing 10 of 108094 citations.

Impact of residual angina on long-term clinical outcomes after percutaneous coronary intervention or coronary artery bypass graft for complex coronary artery disease
Ono, Masafumi , Serruys, Patrick W. , Kawashima, Hideyuki , Lunardi, Mattia , Wang, Rutao , Hara, Hironori , Gao, Chao , Garg, Scot , O’Leary, Neil , Holmes, David R. , Morice, Marie‐Claude, Davierwala, Piroze , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Head, Stuart J., Mohr, Friedrich‐Wilhelm, Mack, Michael J. , Cohen, David Jonathan , Serruys, Patrick W , Garg, Scot , Onuma, Yoshinobu , Wykrzykowska, Joanna J. , Piek, Jan J , Kappetein, A. Pieter , Noack, Thilo , Spertus, John A. , Investigators, for the SYNTAX Extended Survival

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 24, 2022 | Volume: 9 | Issue: 5 | Pages: 490-501

10.1093/ehjqcco/qcac052 | PMID 36001991 Get It

Abstract Aims The aim of this study was to investigate the impact on 10-year survival of patient-reported anginal status at 1 year following percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in patients with left main coronary artery disease (LMCAD) and/or three-vessel CAD (3VD). Methods and results In this post hoc analysis of the randomized SYNTAX Extended Survival study, patients were classified as having residual angina (RA) if their self-reported Seattle Angina Questionnaire angina frequency (SAQ-AF) scale was ≤90 at the 1-year follow-up post-revascularization with PCI or CABG. The primary endpoint of all-cause death at 10 years was compared between the RA and no-RA groups. A sensitivity analysis was performed using a 6-month SAQ-AF. At 1 year, 373 (26.1%) out of 1428 patients reported RA. Whilst RA at 1 year was an independent correlate of repeat revascularization at 5 years [18.3 vs. 11.5%; adjusted hazard ratio (HR): 1.54; 95% confidence interval (CI): 1.10–2.15], it was not associated with all-cause death at 10 years (22.1 vs. 21.6%; adjusted HR: 1.11; 95% CI: 0.83–1.47). These results were consistent when stratified by the modality of revascularization (PCI or CABG) or by anginal frequency. The sensitivity analysis replicating the analyses based on 6-month angina status resulted in similar findings. Conclusion Among patients with LMCAD and/or 3VD, patient-reported RA at 1 year post-revascularization was independently associated with repeat revascularization at 5 years; however, it did not significantly increase 10-year mortality, irrespective of the primary modality of revascularization or severity of RA.
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2
Mudrick, Haley , Massey, Shane , McGlinch, Erin B. , Parrett, Brian J. , Hemsath, Jack R. , Barry, Mary E., Rubin, Jeffrey D. , Uzendu, Chisom, Hansen, Michael J. , Erskine, Courtney L. , Keulen, Virginia P. Van , Drelich, Aleksandra , Panos, Joseph A. , Peikert, Tobias, Block, Matthew S. , Tseng, Chien‐Te K. , Olivier, Gloria , Barry, Michael A. , Mudrick, Haley E , Van Keulen, Virginia P , Fida, Madiha , Suh, Gina A , Block, Matthew S , Tseng, Chien-Te Kent , Olivier, Gloria , Barry, Michael A , Fida, Madiha , Suh, Gina A.

Mayo Clinic

Science Advances | August 24, 2022 | Volume: 8 | Issue: 34 | Pages: No page available

10.1126/sciadv.abm8563 | PMID 36001674 Get It

Most gene-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are nonreplicating vectors. They deliver the gene or messenger RNA to the cell to express the spike protein but do not replicate to amplify antigen production. This study tested the utility of replication in a vaccine by comparing replication-defective adenovirus (RD-Ad) and replicating single-cycle adenovirus (SC-Ad) vaccines that express the SARS-CoV-2 spike protein. SC-Ad produced 100 times more spike protein than RD-Ad and generated significantly higher antibodies against the spike protein than RD-Ad after single immunization of Ad-permissive hamsters. SC-Ad–generated antibodies climbed over 14 weeks after single immunization and persisted for more than 10 months. When the hamsters were challenged 10.5 months after single immunization, a single intranasal or intramuscular immunization with SC-Ad-Spike reduced SARS-CoV-2 viral loads and damage in the lungs and preserved body weight better than vaccination with RD-Ad-Spike. This demonstrates the utility of harnessing replication in vaccines to amplify protection against infectious diseases.
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
Loftus, Edward V. , Vermeire, Séverine , Feagan, Brian G. , Brun, Franck‐Olivier Le , Oortwijn, Alessandra , Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Loftus, Edward V , Vermeire, Séverine , Moerch, Ulrik

Mayo Clinic

Journal of Crohn's and Colitis | August 24, 2022 | Volume: 17 | Issue: 2 | Pages: 211-220

10.1093/ecco-jcc/jjac122 | PMID 36006011 Get It

Abstract Background and Aims Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderately to severely active UC. Methods These post hoc analyses assessed 1-, 3-, 6-, and 8-month rates of corticosteroid-free clinical remission at Week 58 and change in median daily prednisone-equivalent dose over time. A matching-adjusted indirect comparison [MAIC] of maintenance studies assessed corticosteroid-free remission with filgotinib 200 mg, intravenous vedolizumab, subcutaneous vedolizumab, and oral tofacitinib. Results The Maintenance Study full analysis set included 199 patients receiving filgotinib 200 mg and 98 receiving placebo. Among patients receiving corticosteroids at Maintenance Study baseline, at Week 58, 30.4%, 29.3%, 27.2%, and 21.7% receiving filgotinib had been in corticosteroid-free remission for ≥1, ≥3, ≥6, or ≥8 months, respectively, versus 6.4% receiving placebo across thresholds [p <0.05]. Median daily prednisone-equivalent dose decreased from 17.5 mg/day to 10.0 mg/day with filgotinib treatment during the Maintenance Study. Based upon the MAIC, filgotinib was associated with greater likelihood of corticosteroid-free clinical remission versus intravenous vedolizumab (odds ratio [OR], 15.2; 95% confidence interval [CI], 1.6–139.9; p <0.05]) and similar odds to subcutaneous vedolizumab [OR, 3.8; CI, 0.2–63.8; p = 0.36] in biologic-naïve patients, and similar odds to tofacitinib overall [OR, 2.0; 0.4–9.1; p = 0.39]. Conclusions Filgotinib 200 mg demonstrated corticosteroid-sparing effects and maintained corticosteroid-free clinical remission in patients with UC. MAIC results should be interpreted cautiously given the large CIs and differences in study design and patient populations. [ClinicalTrials.gov: NCT02914522].
Women Leadership in Liver Transplantation—Results of an International Survey
Rosmalen, Marieke de Rosner – van, Adelmann, Dieter , Berenguer, Marina , Watt, Kymberly D. , Man, Nancy Kwan, Burra, Patrizia , Berenguer, Marina , Rosmalen, Marieke de Rosner-Van , Berlakovich, Gabriela , Francoz, Claire , Selzner, Nazia , Pai, Sher‐Lu

Mayo Clinic

Transplantation | August 24, 2022 | Volume: 106 | Issue: 9 | Pages: 1699-1702

10.1097/tp.0000000000004034 | PMID 36001485 Get It

Background. The International Liver Transplantation Society (ILTS) has placed a strong focus on achieving gender equality and equity in liver transplant (LT). We aimed to understand gender distribution in leadership positions among LT physicians around the world and within ILTS. Methods. In 2019, the ILTS Equality, Diversity, and Inclusion Committee distributed a survey to obtain granular data on gender and characteristics of transplant physicians as well as those in leadership positions in each center. Additionally, data were collected on the gender composition of the ILTS membership, council, chairpersons, and committees and from the United Network for Organ Sharing. Results. Data were collected from 243 transplant centers. Thirty-two (13.2%) had at least 1 woman as the director of LT, chief of transplant surgery, or chief of transplant hepatology. Of the 243 centers, 133 reported the age and gender of the leadership personnel. Women physicians comprised 152 of the 833 transplant surgeons (18.2%) and 298 of the 935 hepatologists (31.9%). Among the 1331 ILTS physician members, 588 (44.2%) provided gender information in their member profiles, and 155 (26.3%) identified themselves as women. Of the 26 ILTS leadership positions, 7 (26.9%) were held by women. Conclusions. This analysis of worldwide gender distribution in the LT physician workforce showed notable gender disparity in LT leadership around the globe and within the ILTS. These data provide a launching point for promoting and achieving gender equality and equity in LT.
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
Deek, Matthew P. , Sutera, Philip , Deek, Rebecca A. , Fonteyne, Valérie , Mendes, Adrianna A. , Decaestecker, Karel , Kiess, Ana P. , Phillips, Ryan , Bruycker, Aurélie De , Mishra, Mark V. , Rana, Zaker , Molitoris, Jason K. , Lambert, Bieke , Delrue, Louke , Lowe, Kathryn, Bultijnck, Renée , Villeirs, Geert , Man, Kathia De , Ameye, Filip , DeWeese, Theodore L. , Feng, Felix Y. , Wyatt, Alexander W. , Diehn, Maximillian, Bentzen, Søren M. , Joniau, Steven , Vanhaverbeke, Friedl, Meerleer, Gert De , Antonarakis, Emmanuel S. , Antonarakis, Emmanuel S. , Sutera, Philip , Phillips, Ryan , De Bruycker, Aurélie , Rana, Zaker , Molitoris, Jason , Wang, Hailun , Verbeke, Sofie , Van Dorpe, Jo , Bultijnck, Renée , Villeirs, Geert , Paller, Channing J , Feng, Felix Y , Wyatt, Alexander , Pienta, Kenneth J , Diehn, Maximillian , Bentzen, Soren M , Joniau, Steven , Antonarakis, Emmanuel S , Berlin, Alejandro , Siva, Shankar , Ost, Piet , Tran, Phuoc T , Mishra, Mark V , Antonarakis, Emmanuel S , Eecken, Kim Van der , Lumen, Nicolaas , Song, Daniel Y. , Paller, Channing J. , Lotan, Tamara Levin

Mayo Clinic

Journal of Clinical Oncology | August 24, 2022 | Volume: 40 | Issue: 29 | Pages: 3377-3382

10.1200/jco.22.00644 | PMID 36001857 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/ 2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.
Genomic profiling for clinical decision making in lymphoid neoplasms
Leval, Laurence de , Alizadeh, Ash A. , Bergsagel, P. Leif , Campo, Elı́as , Davies, Andrew , Doǧan, Ahmet , Fitzgibbon, Jude , Horwitz, Steven M. , Melnick, Ari , Morice, William G. , Nadel, Bertrand , Rosenquist, Richard , Rossi, Davide , Advani, Ranjana H. , Allen, Carl E. , Ansell, Stephen M. , Chan, Wing C. , Cook, James R. , Cook, Lucy , d’Amore, Francesco, Dirnhofer, Stefan , Dreyling, Martin , Dunleavy, Kieron , Hodson, Daniel J. , Klapper, Wolfram , Kim, Won Seog , King, Rebecca L. , Ko, Young Hyeh , LaCasce, Ann S. , Lenz, Georg , Pasqualucci, Laura , Rosenwald, Andreas , Miguel, Jesús F. San , Staudt, Louis M. , Weigert, Oliver , Wilson, Wyndham H. , Wu, Catherine J. , Bagg, Adam , Dirnhofer, S , Bergsagel, P. Leif , de Leval, Laurence , Melnick, Ari , Morin, Ryan D , Nadel, Bertrand , Pileri, Stefano , Rosenquist, Richard , Salaverria, Itziar , Steidl, Christian , Treon, Steven , Zelenetz, Andrew D , Allen, Carl E , Ansell, Stephen M , Chan, Wing C , Cook, James R , Cook, Lucy B , d'Amore, Francesco , Dreyling, Martin , Dunleavy, Kieron , Feldman, Andrew L , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Gribben, John G. , Hermine, Olivier , Hodson, Daniel J , Hsi, Eric D , Inghirami, Giorgio , Jaffe, Elaine S , Karube, Kennosuke , Kataoka, Keisuke , Klapper, Wolfram , King, Rebecca L , Hyeh, Young , LaCasce, Ann Steward , Lenz, Georg , Piris, Miguel , Pittaluga, Stefania , Pasqualucci, Laura , Quintanilla-Martinez, Leticia , Rodig, Scott J , Rosenwald, Andreas , Salles, Gilles A , San-Miguel, Jesus , Savage, Kerry J , Sehn, Laurie H , Semenzato, Gianpietro , Staudt, Louis M , Swerdlow, Steven H , Tam, Constantine S , Trotman, Judith , Vose, Julie , Weigert, Oliver , Wilson, Wyndham H , Winter, Jane N , Wu, Catherine J , Zinzani, Pier Luigi , Zucca, Emanuele , Bagg, Adam , Scott, David W , Morice, William George , Campo, Elías , Advani, Ranjana H , Dogan, Ahmet , Davies, Andrew , Fitzgibbon, Jude , Horwitz, Steven M , Alizadeh, Ash A , Pileri, Stefano , Salaverría, Itziar , Steidl, Christian , Treon, Steven P. , Zelenetz, Andrew D. , Feldman, Andrew L. , Ghia, Paolo , Hermine, Olivier , Hsi, Eric D. , Inghirami, Giorgio , Jaffe, Elaine S. , Karube, Kennosuke , Martin-Subero, Jose Ignacio , Piris, Miguel Á. , Pittaluga, Stefania , Quintanilla‐Martínez, Leticia , Salles, Gilles , Savage, Kerry J. , Sehn, Laurie H. , Swerdlow, Steven H. , Tam, Constantine S. , Vose, Julie M. , Winter, Jane N. , Zinzani, Pier Luigi , Zucca, Emanuele , Scott, David W.

Mayo Clinic

Blood | August 24, 2022 | Volume: 140 | Issue: 21 | Pages: 2193-2227

10.1182/blood.2022015854 | PMID 36001803 Get It

Abstract With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.
Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative Disorders
Guitart, Joan , Mangold, Aaron R. , Martínez‐Escala, Maria Estela , Walker, Christina J. , Comfere, Nneka I. , Pulitzer, Mellissa, Pincus, Laura B. , Kumar, Erica S., Wang, Erica Bo Kyung, Park, Katherine E., Espinosa, Maria L., Mangold, A R , Rieger, Kerri E. , Torres‐Cabala, Carlos A. , Duvic, Madeleine , Kim, Youn H , Horwitz, Sarah McCue

Mayo Clinic

JAMA Dermatology | August 24, 2022 | Volume: 158 | Issue: 10 | Pages: 1167

10.1001/jamadermatol.2022.3347 | PMID 36001337 Get It

ImportanceThere is a knowledge gap about subcutaneous panniculitis-like T-cell lymphoma (SPTCL) owing to its rarity and diagnostic difficulty, resulting in an absence of well-documented large case series published to date.ObjectiveTo generate consensus knowledge by a joint multi-institutional review of SPTCL and related conditions.Design, Setting, and ParticipantsThis retrospective clinical and pathological review included cases initially diagnosed as SPTCL at 6 large US academic centers. All cases were reviewed by a group of pathologists, dermatologists, and oncologists with expertise in cutaneous lymphomas. Through a process of group consensus applying defined clinical and pathological diagnostic criteria, the cohort was classified as (1) SPTCL or (2) adipotropic lymphoproliferative disorder (ALPD) for similar cases with incomplete histopathological criteria for SPTCL designation.ExposuresCases of SPTCL diagnosed between 1998 and 2018.Main Outcomes and MeasuresThe main outcome was disease presentation and evolution, including response to therapy, disease progression, and development of hemophagocytic lymphohistiocytosis.ResultsThe cohort of 95 patients (median [range] age, 38 [2-81] years; female-to-male ratio, 2.7) included 75 cases of SPTCL and 20 cases of ALPD. The clinical presentation was similar for both groups with multiple (61 of 72 [85%]) or single (11 of 72 [15%]) tender nodules mostly involving extremities, occasionally resulting in lipoatrophy. Hemophagocytic lymphohistiocytosis (HLH) was only observed in SPTCL cases. With a mean follow-up of 56 months, 60 of 90 patients (67%) achieved complete remission with a median (range) of 3 (1-7) cumulative therapies. Relapse was common. None of the patients died of disease progression or HLH. Two patients with ALPD eventually progressed to SPTCL without associated systemic symptoms or HLH.Conclusions and RelevanceIn this case series of patients initially diagnosed as having SPTCL, results showed no evidence of systemic tumoral progression beyond the adipose tissue. The SPTCL experience in this study confirmed an indolent course and favorable response to a variety of treatments ranging from immune modulation to chemotherapy followed by hematopoietic stem cell transplantation. Morbidity was primarily associated with HLH.
The Importance of Physicians Voting in the US—Reply
Hoyt, David B., Barpujari, Awinita , Singh, Rohin

Mayo Clinic

JAMA Surgery | August 24, 2022 | Volume: 157 | Issue: 11 | Pages: 1067

10.1001/jamasurg.2022.3699 | PMID 36001307 Get It

Spontaneous Volumetric Tumor Regression During Wait-and-Scan Management of 952 Sporadic Vestibular Schwannomas
Marinelli, John P. , Killeen, Daniel E. , Schnurman, Zane , Nassiri, Ashley M. , Lees, Katherine A. , Lohse, Christine M. , Roland, Thomas, Golfinos, John G. , Link, Michael J. , Carlson, Matthew L. , Hunter, Jacob B. , Kondziolka, Douglas

Mayo Clinic

Otology & Neurotology | August 24, 2022 | Volume: 43 | Issue: 9 | Pages: e1034-e1038

10.1097/mao.0000000000003651 | PMID 36001695 Get It

Objective Spontaneous tumor shrinkage during wait-and-scan management of sporadic vestibular schwannoma is generally considered an uncommon phenomenon. However, most data informing this understanding stem from single-slice linear tumor measurements taken in the axial imaging plane. The objective of the current work was to characterize the regression capacity of sporadic vestibular schwannomas using volumetric tumor measurements. Study Design Retrospective cohort study using slice-by-slice, three-dimensional volumetric tumor measurements. Setting Three tertiary referral centers. Patients Patients with sporadic vestibular schwannoma. Interventions Wait-and-scan. Main Outcome Measures Regression-free survival rates with regression defined as a decrease of at least 20% of the tumor volume. Results Among 952 patients undergoing a total of 3,505 magnetic resonance imaging studies during observation, 123 experienced volumetric tumor regression after diagnosis at a median of 1.2 years (interquartile range, 0.6–2.9 yr). Volumetric regression-free survival rates (95% confidence interval; number still at risk) at 1, 3, and 5 years after diagnosis were 94% (92–95%; 662), 86% (83–89%; 275), and 78% (73–82%; 132), respectively. Among 405 patients who demonstrated an initial period of tumor growth but continued wait-and-scan management, 48 experienced volumetric regression at a median of 1.2 years (interquartile range, 0.8–2.6 yr) after initial growth. Volumetric regression-free survival rates at 1, 3, and 5 years after initial growth were 94% (92–97%; 260), 84% (79–89%; 99), and 75% (67–83%; 43), respectively. Ultimately, only 82 of the 952 patients studied showed exclusively volumetric tumor regression (i.e., without any periods of tumor growth) by the time of last follow-up. Conclusion Spontaneous volumetric tumor shrinkage during wait-and-scan management occurs more frequently than suggested by previous studies using linear tumor measurements and can even occur after previous episodes of documented tumor growth. These data further highlight the dynamic nature of vestibular schwannoma growth. To this end, the application of natural history data to patient management requires a nuanced approach that parallels the complex tumor behavior of vestibular schwannoma.